Amycretin is essentially a single molecule meant to do the work of CagriSema, a combination treatment of obesity and weight-loss drug semaglutide and amylin analogue, cagrilintide. The oral version is intended for once-daily use, compared to once-weekly for CagriSema. https://www.fiercebiotech.com/biotech/novo-nordisk-rd-spend-jumps-35-thanks-soaring-sales-amycretin-plans-advance